A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance.
David F JarrardMikolaj FilonWei HuangTom HavighurstKatina DeShongKyungMann KimBadrinath R KonetyDaniel SaltzsteinHasan MukhtarBarbara WollmerChen SuenMargaret G HouseHoward L ParnesHoward H BaileyPublished in: The Prostate (2020)
PFE administration for 12-month was well-tolerated and the protocol followed in an active surveillance population. Analyses suggest that PFE contains bioactive compounds capable of altering biomarkers involving oxidative stress and androgen signaling in prostate tumor and normal-appearing adjacent tissue. No alterations in the IGF axis were noted. This finding of study adherence and target activity provides a rationale for the further investigation of PFE in the active surveillance population.
Keyphrases
- phase ii
- prostate cancer
- double blind
- clinical trial
- open label
- oxidative stress
- placebo controlled
- phase iii
- radical prostatectomy
- randomized controlled trial
- type diabetes
- adipose tissue
- dna damage
- ischemia reperfusion injury
- pi k akt
- binding protein
- middle aged
- anti inflammatory
- metabolic syndrome
- glycemic control
- signaling pathway
- benign prostatic hyperplasia
- induced apoptosis